New reports from American College of Chest Physicians reveal people who partake in marijuana usage had better health outcomes against Covid-19 virus compared to those who did not use marijuana.
https://youtu.be/uxarZ6tK6nc
Study: Cannabis Compound CBD May Help Prevent, Treat COVID
NOW HERE'S SOME INTERESTING NEWS: CANNABIDIOL INHIBITS SARS-COV-2 REPLICATION IN HUMAN CELLS AND MICE
The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused widespread morbidity and mortality across the globe ever since it started in late 2019. Despite the availability of a selection of COVID-19 vaccines, SARS-CoV-2 and its newly emerging variants are spreading worldwide, stressing the need for alternative solutions such as effective treatments. Unfortunately, despite a collective global effort, only limited therapies have been identified so far that can block SARS-CoV-2 replication and viral production.
ABOUT THE STUDY
In the current study, researchers used human A549 lung carcinoma, human lung Calu3 cells, and Vero E6 monkey kidney epithelial cells for assessing the effect of CBD on SARS-CoV-2 replication. CBD and related compounds were isolated and identified by 1D- 1H nuclear magnetic resonance (NMR) analysis and compared with the 1H iterative full spin analysis (HiFSA) profile of CBD.
For assessing the influence of CBD on the endoplasmic reticulum (ER) stress response, gene set enrichment analysis (GSEA) was used for quantifying X-box binding protein 1 (XBP1) splicing using ribonucleic acid (RNA) sequencing gene expression data, followed by confirmation using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Inositol-requiring enzyme 1 α (IRE1α) knockout cells and anti-interferon blocking antibodies were used for assessing the effect of CBD on IRE1α and interferons.
FINDINGS
The researchers observed that pre-treatment of A549-ACE-2 human lung carcinoma cell lines with 0-10 µM CBD (97% purity with congeneric cannabinoids <1%) before infection with SARS-CoV-2 or α, β or γ variants potently inhibited SARS-CoV-2 viral replication with an EC50 of 1µM. In addition, CBD also inhibited SARS-CoV-2 replication in human Calu3 lung and Vero E6 monkey kidney epithelial cells.
According to researchers, except for CBD, none of the closely related CBD congeners-such as tetrahydrocannabinol (THC), cannabidivarin (CBDV), cannabidiolic acid (CBDA), cannabichromene (CBC), or cannabigerol inhibited SARS-CoV-2 infection. Perhaps combining CBD with THC (1:1) significantly suppressed CBD efficacy consistent with competitive inhibition. A metabolite of CBD- 7-hydroxy-cannabidiol (7-OH-CBD) effectively inhibited SARS-CoV-2 replication in A549 angiotensin-converting enzyme 2 (ACE2) cells at a non-toxic level.
No effect of CBD was observed on ACE2 receptor expression on three cells lines used in the study. CBD showed no effect on viral entry but was 95-99% effective at inhibiting SARS-CoV-2 spike protein expression in host cells post entry. CBD did not affect viral protein processing by viral main protease (Mpro) or papain-like protease (PLpro), showing that CBD targets host cell processes.
https://www.news-medical.net/news/20220126/Cannabidiol-inhibits-SARS-CoV-2-replication-in-human-cells-and-mice.aspx
CAN CBD FIGHT COVID-19?
A new study published in Science Advances reports evidence that cannabidiol, a product of the cannabis plant, can inhibit infection by SARS-CoV-2 in human cells and in mice. SARS-CoV-2 is the virus that causes COVID-19.
The study, co-authored by researchers from the University of Illinois Chicago and the University of Chicago, found that pharmaceutical-grade cannabidiol showed a significant negative association with SARS-CoV-2 replication.
To study the effect of cannabidiol, commonly called CBD, the researchers first treated human lung cells with a non-toxic dose of CBD for two hours. Then they exposed the cells to SARS-CoV-2 and monitored them for the virus and the viral spike protein, which binds to human cells. While CBD did not affect the ability of SARS-CoV-2 to enter cells, the researchers observed that when above a certain threshold concentration, CBD inhibited the virus’s ability to replicate early in the infection cycle — approximately six hours after the virus had already infected the cell. Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.
The researchers also studied the effect of CBD on viral replication in animals. The team showed that pretreatment with CBD for one week prior to infection suppressed infection both in the lung and the nasal passages of mice.
https://today.uic.edu/can-cbd-fight-covid-19
ANTI-INFLAMMATORY AND ANTIVIRAL EFFECTS OF CANNABINOIDS ... - MDPI
CANNABIDIOL INHIBITS SARS-COV-2 REPLICATION THROUGH INDUCTION OF THE HOST ER STRESS AND INNATE IMMUNE RESPONSES
LONG CHI NGUYEN HTTPS://ORCID.ORG/0000-0002-4637-2331DONGBO YANG HTTPS://ORCID.ORG/0000-0002-8343-5477VLAD NICOLAESCU HTTPS://ORCID.ORG/0000-0002-6347-0232THOMAS J. BEST HTTPS://ORCID.ORG/0000-0003-0654-6250HALEY GULA HTTPS://ORCID.ORG/0000-0002-8475-7435DIVYASHA SAXENAJON D. GABBARDSHAO-NONG CHEN HTTPS://ORCID.ORG/0000-0003-0748-0863TAKASHI OHTSUKI[...]MARSHA RICH ROSNER HTTPS://ORCID.ORG/0000-0001-6586-8335 +24 authors Authors Info & Affiliations
SCIENCE ADVANCES - 20 Jan 2022 - Vol 8, Issue 8
DOI: 10.1126/sciadv.abi6110
https://www.science.org/doi/10.1126/sciadv.abi6110
CANNABIDIOL INHIBITS SARS-COV-2 REPLICATION AND PROMOTES THE HOST INNATE IMMUNE RESPONSE
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987002/
RESEARCHERS RECOMMEND CLINICAL TRIALS FOR CBD TO PREVENT COVID-19 BASED
https://news.uchicago.edu/story/researchers-recommend-clinical-trials-cbd-prevent-covid-19-based-promising-animal-data
STUDY FINDS CANNABIS COMPOUNDS PREVENT INFECTION BY COVID-19 VIRUS
https://www.forbes.com/sites/ajherrington/2022/01/11/study-finds-cannabis-compounds-prevent-infection-by-covid-19-virus/
https://www.forbes.com/sites/chrisroberts/2022/01/21/another-study-finds-cannabis-compound-cbd-might-prevent-fight-covid-19-infection/
CANNABIDIOL AND SARS-COV-2 INFECTION
Department of Epidemiology-Data-Biostatistics, Delegation of Clinical Research and Innovation (DRCI), Foch Hospital, Suresnes, France
Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.
https://www.frontiersin.org/articles/10.3389/fimmu.2022.870787/full
New Research Suggests High-Purity CBD May Help Block COVID-19 Virus From Replicating \\\
Cannabis compound inhibits SARS-CoV-2 replication in human lung cells \\\
CBD Stops Covid-19 From Replicating in Human Cells, Lab Study Finds \\\
Groundbreaking COVID-19 Study Shows CBD May Help Inhibit Infection
Comments
Post a Comment